News
Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the ...
15hon MSN
Healthy Returns: Eli Lilly’s chief scientific officer breaks down the latest obesity pill data
Eli Lilly's Daniel Skovronsky talks the latest orforglipron trial, while UnitedHealth Group CEO Stephen Hemsley is moving ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
While existing GLP-1 medications have shown greater weight loss than Lilly’s oral medication, this option targets both weight loss and type 2 diabetes in patients.
Virginia lawmakers have approved two proposed economic development packages for advanced pharmaceutical manufacturing plants ...
20hon MSN
Cramer's Stop Trading: Eli Lilly
Jim Cramer breaks down why he's keeping an eye on shares of Eli Lilly. This Myrtle Beach restaurant got such a low inspection ...
Eli Lilly (LLY) announced positive results from the Phase 3 ATTAIN-2 trial for orforglipron, a potential treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback